Evidence map›Paper›PMID 17999162›Full record

ArticlePharmaceutical research2008

Modulation of tumor necrosis factor-mediated cell death by fullerenes.

Ljubica Harhaji, Aleksandra Isakovic, Ljubica Vucicevic, Kristina Janjetovic, Maja Misirkic, Zoran Markovic, Biljana Todorovic-Markovic, Nadezda Nikolic, Sanja Vranjes-Djuric, Zoran Nikolic and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ljubica HarhajiInstitute for Biological Research, Belgrade, Serbia.
Aleksandra Isakovic
Ljubica Vucicevic
Kristina Janjetovic
Maja Misirkic
Zoran Markovic
Biljana Todorovic-Markovic
Nadezda Nikolic
Sanja Vranjes-Djuric
Zoran Nikolic
Vladimir Trajkovic
University of Belgrade · RSInstitute of Economic Sciences · RSVinča Institute of Nuclear Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe fullerene (C60/C70 mixture-C60/70) nanocrystalline suspension prepared by solvent exchange method using tetrahydrofyran (THF/nC60/70) and polyhydroxylated C60/70 [C60/70(OH)n] were compared for their ability to modulate cytotoxicity of the proinflammatory cytokine tumor necrosis factor (TNF). MATERIALS AND

methodsTNF-induced cytotoxicity was assessed in L929 fibrosarcoma cells by crystal violet assay. The type of cell death (apoptosis/necrosis), production of reactive oxygen species, mitochondrial depolarization and caspase activation were determined by flow cytometry using the appropriate reporter dyes.

resultsTHF/nC60/70 augmented, while C60/70(OH)n reduced the cytotoxicity of TNF. The numbers of cells undergoing apoptosis/necrosis, as well as of those displaying the activation of apoptosis-inducing enzymes of caspase family, were respectively increased or reduced by THF/nC60/70 or C60/70(OH)n. The antioxidant N-acetylcysteine and mitochondrial permeability transition inhibitor cyclosporin A each partly blocked the cytotoxic action of TNF, indicating the involvement of oxidative stress and mitochondrial dysfunction in the TNF cytotoxicity. Accordingly, THF/nC60/70 or C60/70(OH)n potentiated or suppressed, respectively, TNF-triggered oxidative stress and mitochondrial depolarization.

conclusionThe ability of different fullerene preparations to modulate TNF-induced oxidative stress and subsequent cell death suggests their potential value in the TNF-based cancer therapy or prevention of TNF-dependent tissue damage.

Indexed as

AnimalsApoptosisCaspasesCell Line, TumorFullerenesMiceMice, Inbred C57BLMitochondriaNecrosisReactive Oxygen SpeciesTumor Necrosis Factor-alphaCaspasesFullerenesReactive Oxygen SpeciesTumor Necrosis Factor-alpha

Identifiers

PMID17999162
OpenAlexW2006218288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.